Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 19;11:181. doi: 10.1186/s13287-020-01682-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Influence of LY294002 treatment on VTN knocked down WJ-MSCs under serum deprivation. WJ-MSCs transfected with a NC siRNA or VTN-targeted esiRNA were treated with PI3kinase pathway inhibitor, LY294002. a qRT-PCR analysis for VTN (n = 3). b Estimation of apoptosis by annexin V analysis. Representative flow cytometry analysis for detection of apoptosis is displayed. c Comparison of the percentages of viable, early apoptotic, and late apoptotic populations between control, NC siRNA-transfected WJ-MSCs treated with LY294002, and VTN esiRNA-transfected WJ-MSCs treated with LY294002 as depicted by the histogram (n = 3). d MTT assay determined the percentage of metabolically viable population of WJ-MSCs upon LY294002 treatment to the VTN knocked down WJ-MSCs under serum deprivation. Each bar represents mean ± SEM (푛n=3). Serum-deprived condition represented as no serum (NS) in the figure (*p < 0.05, ***p < 0.0001)